Last reviewed · How we verify
Choletec (MEBROFENIN)
Choletec (Mebrofenin) is a small molecule drug in the mebrofenin class, used for diagnostic imaging of the biliary system. It works by being taken up by the liver and excreted into the bile, allowing for visualization of the bile ducts and gallbladder. Choletec is used to diagnose conditions such as gallstones, bile duct obstruction, and liver disease. The commercial status of Choletec is not specified, but it is likely patented. Key safety considerations include potential allergic reactions and interactions with other medications.
At a glance
| Generic name | MEBROFENIN |
|---|---|
| Drug class | mebrofenin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Hepatobiliary imaging
Common side effects
- Urticaria
- Rash
- Chills
- Nausea
- Death
Key clinical trials
- Liver Function Investigation With SPECT
- Functional Liver After SBRT
- TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery (NA)
- Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration (NA)
- HepaRAS Trial: Changes in Hepatectomy Risk Assessment When Using Mebrofenin HIDA (NA)
- Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients With Liver Fibrosis
- Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin (PHASE1)
- Interstage Assessment of Remnant Liver Function in ALPPS
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Choletec CI brief — competitive landscape report
- Choletec updates RSS · CI watch RSS